This dysregulated activation results from mutations that are frequent in ERα‐positive breast cancers, or the overexpression of growth factor receptors that activate such pathways, such as the EGF receptor (EGFR), which has been linked to endocrine resistance as well [15]. This evidence concerns the gene ESR1 and breast carcinoma.